



CAPSTONE
HEALTH ALLIANCE

Harm Reduction Therapeutics Partners with Capstone Health Alliance to Expand Access to Life-Saving Naloxone Nationwide

**Partnership will enhance distribution of RiVive® 3 mg naloxone nasal spray,
advancing compassionate overdose response across the United States.**

FOR IMMEDIATE RELEASE

[January 28, 2026]

Harm Reduction Therapeutics, Inc. (HRT), the only 501(c)(3) non-profit pharmaceutical manufacturer focused on making life-saving naloxone accessible, is proud to announce a new partnership with Capstone Health Alliance. This strategic and collaborative move will help to increase the distribution of HRT's flagship product, FDA-approved over-the-counter (OTC) RiVive® 3 mg naloxone nasal spray. With Capstone Health Alliance's vast network of providers, this collaboration represents a major step toward making overdose reversal medication more affordable, accessible, and compassionate in communities across the United States, supporting frontline harm reduction efforts and empowering caregivers, first responders, and families to save lives.

A Shared Commitment to Compassionate Opioid Overdose Response: Unlike higher-dose naloxone products, RiVive 3 mg naloxone nasal spray promotes Compassionate Overdose Response™. It delivers the lowest effective dose of OTC intranasal naloxone available in the United States to reverse opioid overdose while reducing the risk of precipitated withdrawal symptoms. RiVive offers Compassionate Overdose Response intended to rescue and not punish the person experiencing an overdose. Competitive products are formulated with higher doses of naloxone which can increase the risks of precipitated withdrawal symptoms caused from using more naloxone than may be necessary to reverse an opioid overdose. The partnership between Harm Reduction Therapeutics and Capstone Health Alliance represents a significant moment for the expansion of access to Compassionate Overdose Response and the support of harm reduction efforts across the country.

Statement from Leadership

“Our partnership with Capstone Health Alliance represents an important milestone in our mission to make naloxone accessible to everyone,” said Michael Hufford, Ph.D., Co-Founder and CEO of Harm Reduction Therapeutics. “By leveraging Capstone’s reach and relationships, we’re not only expanding the availability of RiVive, but also advancing a compassionate, community-based approach to opioid overdose reversal and saving lives.”

“Capstone is keenly focused on helping our members address the challenges they face providing care to their communities, which certainly includes the ongoing opioid crisis,” stated Capstone’s VP of Pharmacy Services, Fred J. Pane, R.Ph., FASHP, FABC. “Through our partnership with Harm Reduction Therapeutics and their intranasal naloxone product RiVive, we can offer a unique option to Capstone members that will truly make a difference in saving countless lives.”

FDA Approval and Timely Response to the Crisis

The FDA's approval of RiVive in July 2023 came at a crucial time given the escalating opioid crisis, which continues to claim tens of thousands of lives annually. There is an urgent need for accessible opioid overdose reversal solutions, especially in the context of increasing overdose rates. RiVive addresses this need by providing a reliable, easy-to-use, OTC option in an effective low-dose nasal spray, making it an essential tool in combating opioid overdoses. Together, Harm Reduction Therapeutics and Capstone Health Alliance aim to ensure that this life-saving medication reaches more people who need this vital harm reduction resource, and who deserve to have this option as part of a Compassionate Overdose Response practice.

Why 3 mg Matters: A Safer, More Compassionate Choice

Precipitated withdrawal symptoms can cause significant discomfort and distress, posing additional challenges for professional and non-professional caregivers alike. RiVive's 3 mg dose of naloxone reduces these risks by providing a lower yet effective dose, helping to enable safer management of overdoses.

Designed for Home and Community Use

The increasing prevalence of opioid use and the associated risk of overdose nationwide necessitates reliable, user-friendly rescue medications. RiVive naloxone HCl nasal spray 3 mg is designed for ease of use, making it an ideal option for emergency situations at home and in communities without the need for a prescription. It aligns with the medical principle of administering the lowest effective dose, ensuring both efficacy and safety. The reduced likelihood of severe reactions provides peace of mind for caregivers administering the spray.

About Harm Reduction Therapeutics

Harm Reduction Therapeutics, Inc. (HRT) is an independent, 501(c)(3) non-profit pharmaceutical company advancing harm reduction therapies to promote public health. HRT's mission is to save lives that would otherwise be lost to opioid overdose, to prevent opioid overdose deaths in the most compassionate way possible, and to make naloxone available to everyone at a low price. As part of their mission, HRT donates at least 10% of RiVive units produced to underfunded harm reduction organizations. Learn more at <https://harmreductiontherapeutics.org>

About Capstone Health Alliance

Headquartered in Asheville, NC, Capstone Health Alliance is a leading regional group purchasing organization (GPO) that collaborates with hundreds of hospitals and thousands of healthcare providers across the nation. Capstone is dedicated to delivering tangible savings and value, providing actionable data and support to empower informed supply chain decisions, including industry leading education, all to drive down the overall cost of healthcare and enhance the value of care to patients. Learn more at <https://capstonehealthalliance.com>

Contacts:

Catey Galatola Tetro
Director of Sales & Marketing
Harm Reduction Therapeutics, Inc.
sales@harmreductiontherapeutics.org
(888) 412-7454
www.harmreductiontherapeutics.org

Tracey Johnston-Crum
Chief Marketing Officer
Capstone Health Alliance
tjohnston-crum@capstonehealthalliance.com
(828) 418-5050
www.capstonehealthalliance.com

###